When it comes to antitumor drugs, both the physicians who prescribethem and the patients who receive them would agree that betterchemotherapeutic agents are needed. Drugs in common use weredesigned to take advantage of general characteristics of tumorcells such as hormone responsiveness or high rates of cell division.Unfortunately, these properties are also found in some healthycells. This general lack of specificity has led to the use ofdrug doses that straddle a knife edge between efficacy and toxicity.Two recent studies, one by Bryant et al.1 and the other by Farmeret al.,2 suggest that . . . [Full Text of this Article]
Source Information
From the Genome Technology Branch of the National Human Genome Research Institute, National Institutes of Health, Bethesda, Md.
This article has been cited by other articles:
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H.M., de Bono, J. S.
(2009). Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. NEJM
361: 123-134
[Abstract][Full Text]
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Bialkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., Smith, G. C.M., Ashworth, A.
(2006). Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition. Cancer Res.
66: 8109-8115
[Abstract][Full Text]
Ashworth, A.
(2006). Defective Double-Strand DNA Repair and Cancer Susceptibility in BRCA Mutation Carriers. aacredbook
2006: 303-306
[Full Text]